Recent advances in adrenal autoimmunity

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 4, 2009, Pages 333-348

  Falorni, Alberto ^a   Brozzetti, Annalisa ^b   Calcinaro, Filippo ^b   Marzotti, Stefania ^b   Santeusanio, Fausto ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Department of Internal Medicine ^*  (Italy)

Author keywords

21 hydroxylase; Addison's disease; Aire; Autoantibodies; CXCL 10; HLA; Primary ovarian insufficiency; T cell

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AUTOANTIBODY; AUTOANTIGEN; AUTOIMMUNE REGULATOR PROTEIN; CD3 ANTIBODY; CORTICOSTEROID; CORTICOTROPIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENZYME ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMATE DECARBOXYLASE 65; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; P450 SIDE CHAIN CLEAVAGE ANTIBODY; STEROID 17ALPHA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE ANTIBODY; STEROID 21 MONOOXYGENASE; STEROID 21 MONOOXYGENASE ANTIBODY; UNCLASSIFIED DRUG; VITAMIN D;

ADDISON DISEASE; ADRENAL CORTEX CELL; ADRENAL CORTEX INSUFFICIENCY; ADRENAL DISEASE; ANTIBODY DETECTION; AUTOIMMUNE ADDISON DISEASE; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINE SYNDROME TYPE 2; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CELL DESTRUCTION; CLINICAL TRIAL; CORTICOTROPIN TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DOSE RESPONSE; DRUG MEGADOSE; ENDOCRINE OPHTHALMOPATHY; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HLA SYSTEM; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY DIAGNOSIS; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; TH1 CELL;

EID: 69949175953     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.20     Document Type: Review

References (139)

1. Laureti S, Vecchi L, Sanceusanio F, Falorni A. Is the prevalence of Addison's disease underestimated? J. Clin. Endocrinol. Metab. 84, 1762 (1999).
2. Løvas K, Husebye ES. High prevalence and increasing incidence of Addison's disease in western Norway. Clin. Endocrinol. (Oxf.) 56, 787-791 (2002).
3. Oelkers W. Adrenal insufficiency. N. Engl. J. Med. 335, 1206-1212 (1996).
4. Aubourg P. On the front of X-linked adrenoleukodystrophy. Neurochem. Res. 24, 515-520 (1999).
5. Clark AJ, McLoughlin L, Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 341, 461-462 (1993).
6. Addison T. On the constitutional and local effects of disease of the suprarenal capsules. In a collection of the published writing of the late Thomas Addison, MD, physician to Guy's Hospital. New Sydenham Society, London (1868). Reprinted in: Medical Classics 2, 244-293 (1937).
7. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev. 23, 327-364 (2002).
8. Nomura K, Depura H, Saruta T. Addison's disease in Japan: characteristics and changes revealed in a nationwide survey. Intern. Med. 33, 602-606 (1994).
9. The Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Nat. Genet. 17, 399-403 (1997).
10. Neufeld M, Blizzard RM. Polyglandular autoimmune diseases. In: Symposium on Autoimmune Aspects of Endocrine Disorders. Pinchera A, Doniach D, Fenzi GF, Baschieri L (Eds). Academic Press, NY, USA, 357-365 (1980).
11. Nerup J. Addison's disease - clinical studies. A report of 108 cases. Acta Endocrinol. (Copenh.) 76, 127-141 (1974).
12. Kong MF, Jeffcoate W. Eighty-six cases of Addison's disease. Clin. Endocrinol. (Oxf.) 41, 757-761 (1994).
13. Irvine WJ, Stewart AG, Scarth L. A clinical and immunological study of adrenocortical insufficiency (Addison's disease). Clin. Exp. Immunol. 2, 31-69 (1967).
14. McHardy-Young S, Lessof MH, Maisey MN. Serum TSH and thyroid studies in Addison's disease. Clin. Endocrinol. (Oxf.) 1, 45-56 (1974).
15. Irvine WJ, Toft AD, Feek CM. Addison's disease. In: The Adrenal Gland. James VHT (Ed.). Raven Press, NY, USA, 131-164 (1979).
16. De Rosa G, Corsello SM, Cecchini L, Delia Casa S, Testa A. A clinical study of Addison's disease. Exp. Clin. Endocrinol. 90, 232-242 (1987).
17. Papadopoulos KI, Hallengren B. Polyglandular autoimmune syndrome type II in patients with idiopathic Addison's disease. Acta Endocrinol. (Copenh.) 122, 472-478 (1990).
18. Kasperlik-Zaluska AA, Migdalska B, Czarnocka B, Drac-Kaniewska J, Niegowska E, Czech W. Association of Addison's disease with autoimmune disorders - a long-term observation of 180 patients. Postgrad. Med. J. 67, 984-987 (1991).
19. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. J. Autoimmun. 8, 121-130 (1995).
20. Söderbergh A, Winqvist O, Norheim I et al. Adrenal autoantibodies and organ-specific autoimmunity in Addison disease. Clin. Endocrinol. (Oxf.) 45, 453-460 (1996).
21. Neufeld M, MacLaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 60, 355-362 (1981).
22. Anderson JR, Goudie RB, Gray KG, Timbury GC. Autoantibodies in Addison's disease. Lancet 1, 1123-1124 (1957).
23. Blizzard RM, Kyle M. Studies of the adrenal antigens and autoantibodies in Addison's disease. J. Clin. Invest. 42, 1653-1660 (1963).
24. Goudie RB, Anderson JR, Gray KK, Whyte WG. Autoantibodies in Addison's disease. Lancet 1, 1173-1176 (1966).
25. Andrada JA, Bigazzi PL, Andrada E, Milgrom F, Witebsky E. Serological investigation on Addison's disease. Clin. Sci. 206, 1535-1541 (1968).
26. Blizzard RM, Chee D, Davis W. The incidence of adrenal and other autoantibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease). Clin. Exp. Immunol. 2, 19-30 (1967).
27. Wuepper KD, Weigienka LC, Fudenberg HH. Immunologic aspect of adrenocortical insufficiency. Am. J. Med. 46, 206-216 (1969).
28. Irvine WJ, Barnes EW. Addison's disease and associated conditions: with particular references to premature ovarian failure, diabetes mellitus and hypoparathyroidism. In: Clinical Aspects of Immunology. Gell PH, Coombs RRA, Lachman P (Eds). Blackwell, Oxford, UK, 1301-1354 (1974).
29. Elder M, Madaren N, Riley W. Gonadal autoantibodies in patients with hypogonadism and/or Addison disease. J. Clin. Endocrinol. Metab. 52, 1137-1142 (1981).
30. Sotsiou F, Bottazzo GF, Doniach D. Immunofluorescence studies on autoantibodies to steroid-producing cells, and to germline cells in endocrine disease and infertility. Clin. Exp. Immunol. 39, 97-111 (1980).
31. Stechmesser E, Scherbaum WA, Grossman T, Berg PA. An ELISA method for the detection of autoantibodies to adrenal cortex. J. Immunol. Methods 80, 67-76 (1985).
32. Kosowicz J, Gryczynska M, Bottazzo GF. A radioimmunoassay for the detection of adrenal autoantibodies. Clin. Exp. Immunol. 63, 671-679 (1986).
33. Betterle C, Volpato M, Pedini B, Chen S, Rees-Smith B, Furmaniak J. Adrenal-cortex autoantibodies (ACA) and steroid-producing cells autoantibodies (StCA) in patients with Addison's disease: comparison between immunofluorescence and immunoprecipitation assays. J. Clin. Endocrinol. Metab. 84, 618-622 (1999).
34. Falorni A, Laureti S, Nikoshkov A et al. 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Clin. Exper. Immunol. 107, 341-345 (1997).
35. Furmaniak J, Talbot D, Reinwein D, Benker G, Creagh FM, Smith B. Immunoprecipitation of human adrenal microsomal antigen. FEBS Lett. 232, 25-28 (1988).
36. Winqvist O, Karlsson FA, Kämpe O. 21-hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 339, 1559-1562 (1992).
37. Baumann-Antczak A, Wedlock N, Bednarek J et al. Autoimmune Addison's disease and 21-hydroxylase. Lancet 340, 429-430 (1992).
38. Bednarek J, Furmaniak J, Wedlock N et al. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison's disease. FEBS Lett. 309, 51-55 (1992).
39. Krohn K, Uibo R, Aavik E, Peterson P, Savilahti K. Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17α-hydroxylase. Lancet 339, 770-773 (1992).
40. Winqvist O, Gustafsson J, Rorsman F, Karlsson FA, Kämpe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. J. Clin. Invest. 92, 2377-2385 (1993).
41. Falorni A, Nikoshkov A, Laureti S et al. High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinat human 21-hydroxylase. J. Clin. Endocrinol. Metab. 80, 2752-2755 (1995).
42. Colls J, Betterle C, Volpato M, Prentice L, Smith BR, Furmaniak J. Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin. Chem. 41, 375-380 (1995).
43. Tanaka H, Perez MS, Powell M et al. Steroid 21-hydroxylase autoantibodies: measurements with a new immunoprecipitation assay. J. Clin. Endocrinol. Metab. 82, 1440-1446 (1997).
44. Chen S, Sawicka J, Prentice L et al. Analysis of autoantibody epitopes on steroid 21-hydroxylase (21-OH) using a panel of monoclonal antibodies. J. Clin. Endocrinol. Metab. 83, 2977-2986 (1998).
45. Nikoshkov A, Falorni A, Lajic S et al. A conformation-dependent epitope in Addison's disease and other endocrinological autoimmune diseases maps to a carboxyl-terminal functional domain of human steroid 21-hydroxylase. J. Immunol. 162, 2422-2426 (1999).
46. Asawa T, Wedlock N, Baumann-Antczak A, Smith BR, Furmaniak J. Naturally occurring mutations in human steroid 21-hydroxylase influence adrenal autoantibody binding. J. Clin. Endocrinol. Metab. 79, 372-376 (1994).
47. Furmaniak J, Kominami S, Asawa T, Wedlock N, Colls J, Rees-Smith B. Autoimmune Addison's disease. Evidence for a role of steroid 21-hydroxylase autoantibodies in adrenal insufficiency. J. Clin. Endocrinol. Metab. 79, 1517-1521 (1994).
48. Nikfarjam L, Kominami S, Yamazaki T et al. Mechanism of inhibition of cytochrome P450 C21 enzyme activity by autoantibodies from patients with Addison's disease. Eur. J. Endocrinol. 152, 95-101 (2005).
49. Boscaro M, Betterle C, Volpato M, et al. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity block in vivo. J. Clin. Endocrinol. Metab. 81, 2801-2804 (1996).
50. Laureti S, Candeloro P, Aglietti MC et al. Dehydroepiandrosterone, 17α-hydroxyprogesterone and aldosterone responses to the low-dose (1 μg) ACTH test in subjects with preclinical adrenal autoimmunity. Clin. Endocrinol. (Oxf.) 57, 677-683 (2002).
51. Betterle C, Pra CD, Pedini B et al. Assessment of adrenocortical function and autoantibodies in a baby born to a mother with autoimmune polyglandular syndrome type 2. J. Endocrinol. Invest. 27, 618-621 (2004).
52. Bøe AS, Bredholt G, Knappskog PM et al. Autoantibodies against 21-hydroxylase and side-chain cleavage enzyme in autoimmune Addison's disease are mainly immunoglobulin G1. Eur. J. Endocrinol. 150, 49-56 (2004).
53. Perniola R, Falorni A, Clemente MG, Forini F, Accogli E, Lobreglio G. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Eur. J. Endocrinol. 143, 497-503 (2000).
54. Falorni A, Laureti S, Candeloro P et al. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil. Steril. 78, 270-279 (2002).
55. Dal Pra C, Chen S, Furmaniak J et al. Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison's disease. Eur. J. Endocrinol. 148, 565-570 (2003).
56. Bakalov VK, Anasti JN, Calis KA et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil. Steril. 84, 958-965 (2005).
57. Peterson P, Krohn KJ. Mapping of B cell epitopes on steroid 17 α-hydroxylase, an autoantigen in autoimmune polyglandular syndrome type I. Clin. Exp. Immunol. 98, 104-109 (1994).
58. Liiv I, Teesalu K, Peterson P, Clemente MG, Perheentupa J, Uibo R. Epitope mapping of cytochrome P450 cholesterol side-chain cleavage enzyme by sera from patients with autoimmune polyglandular syndrome type 1. Eur. J. Endocrinol. 146, 113-119 (2002).
59. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocrinol. Rev. 18, 107-134 (1997).
60. Arif S, Vallian S, Farzaneh F et al. Identification of 3β-hydroxysteroid-dehydrogenase as a novel target of steroid cell autoantibodies: association of autoantibodies with endocrine autoimmune disease. J. Clin. Endocrinol. Metab. 81, 4439-4445 (1996).
61. Reimand K, Peterson P, Hyoty H et al. 3β-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure. J. Clin. Endocrinol. Metab. 85, 2324-2326 (2000).
62. do Carmo Silva R, Kater CE, Dib SA et al. Autoantibodies against recombinant human steroidogenic enzyme 21-hydroxylase, side-chain cleavage and 17α-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III. Eur. J. Endocrinol. 142, 187-194 (2000).
63. Falorni A, Laureti S, De Bellis A et al. Italian Addison Network Study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 89, 1598-1604 (2004).
64. Betterle C, Scalici C, Presotto F et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J. Endocrinol. 117, 467-475 (1988).
65. De Bellis A, Bizzarro A, Rossi R et al. Remission of subdinical adrenocortical failure in subjects with adrenal autoantibodies. J. Clin. Endocrinol. Metab. 76, 1002-1007 (1993).
66. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N. Engl. J. Med. 30, 1692-1698 (2002).
67. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005).
68. Ludvigsson J, Faresjö M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset Type 1 diabetes. N. Engl. J. Med. 359, 1909-1920 (2008).
69. Mathieu C, Badenhoop K. Vitamin D and Type 1 diabetes mellitus: state of the art. Trends Endocrinol. Metab. 16, 261-266 (2005).
70. De Bellis A, Falorni A, Laureti S et al. Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. J. Clin. Endocrinol. Metab. 86, 675-678 (2001).
71. Betterle C, Volpato M, Rees-Smith B et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. J. Clin. Endocrinol. Metab. 82, 932-938 (1997).
72. Laureti S, De Bellis A, Muccitelli VI et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J. Clin. Endocrinol. Metab. 83, 3507-3511 (1998).
73. Barker JM, Ide A, Hostetler C et al. Endocrine and immunogenetic testing in individuals with Type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population. J. Clin. Endocrinol. Metab. 90, 128-134 (2005).
74. Coco G, Dal Pra C, Presotto F et al. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J. Clin. Endocrinol. Metab. 91, 1637-1645 (2006).
75. Arvat E, Di Vito L, Laffranco F et al. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J. Clin. Endocrinol. Metab. 88, 3141-3146 (2000).
76. Laureti S, Arvat E, Candeloro P et al. Low dose (1 μg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison's disease. Clin. Endocrinol. (Oxf.) 53, 107-115 (2000).
77. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 350, 2068-2079 (2004).
78. Peterson P, Pitkänen J, Sillanpää N, Krohn K. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity. Clin. Exp. Immunol. 135, 348-357 (2004).
79. Candeloro P, Borri Voltattorni C, Perniola R et al. Mapping of human autoantibody epitopes on aromatic L-amino acid decarboxylase. J. Clin. Endocrinol. Metab. 92, 1096-1105 (2007).
80. Alimohammadi M, Bjorklund P, Hallgren A et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N. Engl. J. Med. 358, 1018-1028 (2008).
81. Meloni A, Furcas M, Cetani F et al. Autoantibodies against type I interferons as an additional diagnostic criteria for autoimmune olyendocrine syndrome type I. J. Clin. Endocrinol. Metab. 93, 4389-4397 (2008).
82. Oftedal BE, Wolff AS, Bratland E et al. Radioimmunoassay for autoantibodies against interferon ω; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin. Immunol. 129, 163-169 (2008).
83. Pitkänen J, Vähämurto P, Krohn K et al. Subcellular localization of the autoimmune regulator protein. Characterization of nuclear targeting and transcriptional activation domain. J. Biol. Chem. 276, 19597-19602 (2001).
84. Björses P, Halonen M, Palvimo JJ et al. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am. J. Hum. Genet. 66, 378-392 (2000).
85. Pitkänen J, Doucas V, Sternsdorf T et al. The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein. J. Biol. Chem. 275, 16802-16809 (2000).
86. Bottomley MJ, Collard MW, Huggenvik JI et al. The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation. Nat. Struct. Biol. 8, 626-633 (2001).
87. Cetani F, Barbesino G, Borsari S et al. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis. J. Clin. Endocrinol. Metab. 86, 4747-4752 (2001).
88. Su MA, Giang K, Zumer K et al. Mechanisms of an autoimmune syndrome in mice caused by a dominant mutation in Aire. J. Clin. Invest. 118, 1712-1726 (2008).
89. Halonen M, Eskelin P, Myhre AG et al. AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J. Clin. Endocrinol. Metab. 87, 2568-2574 (2002).
90. Ramsey C, Winqvist O, Puhakka L et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum. Mol. Genet. 11, 397-409 (2002).
91. Anderson MS, Venanzi ES, Klein L et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 298, 1395-1401 (2002).
92. Koh AS, Kuo AJ, Park SY et al. Aire employs a histone-binding module to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity. Proc. Natl Acad. Sci. USA 105, 15878-15883 (2008).
93. Lindh E, Lind SM, Lindmark E et al. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc. Natl Acad. Sci. USA 105, 18466-18471 (2008).
94. Tuovinen H, Pöntynen N, Gylling M et al. γδ T cells develop independently of Aire. Cell. Immunol. 257, 5-12 (2009).
95. Pitt LA, Hubert FX, Scott HS, Godfrey DI, Berzins SP. NKT cell development in the absence of the autoimmune regulator gene (Aire). Eur. J. Immunol. 38, 2689-2696 (2008).
96. Gavanescu I, Benoist C, Mathis D. B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients. Proc. Natl Acad. Sci. USA 105, 13009-13014 (2008).
97. Devoss JJ, Shum AK. Johannes KP et al. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J. Immunol. 181, 4072-4079 (2008).
98. Suzuki E, Kobayashi Y, Kawano O et al. Expression of AIRE in thymocytes and peripheral lymphocytes. Autoimmunity 41, 133-139 (2008).
99. Gardner JM, Devoss JJ, Friedman RS et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321, 843-847 (2008).
100. Pöntynen A, Miettinen A, Petteri Arstila T et al. Aire deficient mice do not develop the same profile of tissue-specific autoantibodies as APECED patients. J. Autoimmun. 27, 96-104 (2006).
101. Ströbel P, Murumägi A. Klein R et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J. Pathol. 211, 563-571 (2007).
102. Meager A, Visvalingam K, Peterson P et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e289 (2006).
103. Liston A, Gray DH, Lesage S et al. Gene dosage-limiting role of Aire in thymic expression, donal deletion, and organ-specific autoimmunity. J. Exp. Med. 200, 1015-1026 (2004).
104. Meyer G, Donner H, Herwig J, Böhles H, Usadel KH, Badenhoop K. Screening for an AIRE-1 mutation in patients with Addison's disease, Type 1 diabetes, Graves' disease and Hashimoto's thyroiditis as well as in APECED syndrome. Clin. Endocrinol. (Oxf.) 54, 335-338 (2001).
105. Torok HP, Tonenchi L, Glas J, Schiemann U, Folwaczny C. No significant association between mutations in exons 6 and 8 of the autoimmune regulator (AIRE) gene and inflammatory bowel disease. Eur. J. Immunogenet. 31, 83-86 (2004).
106. Falorni A, Brozzetti A, La Torre D, Tortoioli C, Gambelunghe G. The association of genetic polymorphisms and autoimmune Addison's disease. Expert Rev. Clin. Immunol. 4(4), 441-456 (2008).
107. Yu L, Brewer KW, Gates S et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J. Clin. Endocrinol. Metab. 84, 328-335 (1999).
108. Myhre AG, Undlien DE, Løvås K et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J. Clin. Endocrinol. Metab. 87, 618-623 (2002).
109. Gambelunghe G, Kockum I, Bini V et al. Retrovirus-like long terminal repeat DQ-LTR13 and genetic susceptibility to type 1 diabetes mellitus and autoimmune Addison's disease. Diabetes 54, 900-905 (2005).
110. Rønningen KS, Keiding N, Green A; EURODIAB ACE Study Group. Correlations between the incidence of childhood-onset Type I diabetes in Europe and HLA genotypes. Diabetologia 44(Suppl. 3), B51-B59 (2001).
111. Gambelunghe G, Falorni A, Ghaderi M et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. J. Clin. Endocrinol. Metab. 84, 3701-3707 (1999).
112. Park YS, Sanjeevi CB, Robles D et al. Additional association of intra-MHC genes, MICA and D6S273, with Addison's disease. Tissue Antigens 60, 155-163 (2002).
113. Skinningsrud B, Husebye ES, Gervin K et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. Eur. J. Hum. Genet. 16, 977-982 (2008).
114. Ghaderi M, Gambelunghe G, Tortoioli C et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J. Clin. Endocrinol. Metab. 91, 4107-4111 (2006).
115. Skinningsrud B, Husebye E, Pearce SH et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 93, 3310-3317 (2008).
116. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol. Cell. Biol. 20, 6185-6194 (2000).
117. Durand B, Sperisen P, Emery P et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16, 1045-1055 (1997).
118. Masternak K, Barras E, Zufferey M et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat. Genet. 20, 273-277 (1998).
119. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19, 331-373 (2001).
120. Nekrep N, Jabrane-Ferrat N, Wolf HM, Eibl MM, Geyer M, Peterlin BM. Mutation in a winged-helix DNA-binding motif causes atypical bare lympocyte syndrome. Nat. Immunol. 3, 1075-1081 (2002).
121. Fontes JD, Kanazawa S, Nekrep N, Peterlin BM. The class II transactivator CIITA is a transcritpional integrator. Microbes Infect. 1, 863-869 (1999).
122. Kanazawa S, Okamoto T, Peterlin BM. Tat competes with CIITA for the binding to PTEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12, 61-70 (2000).
123. Magitta NF, Bøe Wolff AS, Johansson S et al. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and Type 1 diabetes. Genes Immun. 10, 120-124 (2009).
124. Greco DS. Hypoadrenocorticism in small animals. Clin. Tech. Small Anim. Pract. 22, 32-35 (2007).
125. Freeman M, Weetman AP. T and B cell reactivity to adrenal antigens in autoimmune Addison's disease. Clin. Exp. Immunol. 88, 275-279 (1992).
126. Hayashi Y, Hiyoshi T, Takemura T, Kurashima C, Hirokawa K. Focal lymphocytic infiltration in the adrenal cortex of the elderly: immunohistological analysis of infiltrating lymphocytes. Clin. Exp. Immunol. 77, 101-105 (1989).
127. Nerup J, Andersen V, Bendixen G. Anti-adrenal, cellular hypersensitivity in Addison's disease. Clin. Exp. Immunol. 4, 355-363 (1969).
128. Nerup J, Andersen V, Bendixen G. Anti-adrenal, cellular hypersensitivity in Addison's disease. IV. In vivo and in vitro investigations on the mitochondrial fraction. Clin. Exp. Immunol. 6, 733-739 (1970).
129. Rabinowe SL, Jackson RA, Dluhy RG, Williams GH. la-positive T lymphocytes in recently diagnosed idiopathic Addison's disease. Am. J. Med. 77, 597-601 (1984).
130. + regulatory T cells in autoimmune polyglandular syndrome type 11. J. Exp. Med. 199, 1285-1291 (2004).
131. +) T cells. Eur. J. Immunol. 35, 3694-3703 (2005).
132. Husebye ES, Bratland E, Bredholt G, Fridkin M, Dayan M, Mozes E. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodminant T cell epitope. Endocrinology 147, 2411-2416 (2006).
133. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocrine Rev. 28, 492-520 (2007).
134. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 18, 349-356 (2006).
135. Rotondi M, Falorni A, De Bellis A et al. Elevated serum interferon-γ-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J. Clin. Endocrinol. Metab. 90, 2357-2363 (2005).
136. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93, 487-490 (1998).
137. Vendrame F, Segni M, Grassetti D et al. Impaired caspase-3 expression by peripheral T cells in chronic autoimmune thyroiditis and in autoimmune polyendocrine syndrome-2. J. Clin. Endocrinol. Metab. 91, 5064-5068 (2006).
138. Vendrame F, Santangelo C, Misasi R et al. Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus. Eur. J. Endocrinol. 152, 119-125 (2005).
139. + regulatory T cells in the regional lymph node. J. Exp. Med. 202, 771-781 (2005).